Bank of New York Mellon Corp Has $1.05 Million Holdings in Codexis, Inc. (NASDAQ:CDXS)

Bank of New York Mellon Corp grew its position in Codexis, Inc. (NASDAQ:CDXS) by 8.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 220,876 shares of the biotechnology company’s stock after buying an additional 17,429 shares during the quarter. Bank of New York Mellon Corp’s holdings in Codexis were worth $1,054,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Kingswood Wealth Advisors LLC purchased a new stake in shares of Codexis in the 4th quarter valued at approximately $79,000. China Universal Asset Management Co. Ltd. acquired a new stake in Codexis during the 4th quarter valued at $82,000. Intech Investment Management LLC acquired a new stake in Codexis during the 3rd quarter valued at $66,000. Jackson Square Capital LLC purchased a new stake in shares of Codexis in the fourth quarter valued at $210,000. Finally, Inspire Investing LLC acquired a new stake in shares of Codexis in the fourth quarter worth $405,000. 78.54% of the stock is owned by hedge funds and other institutional investors.

Codexis Stock Performance

Shares of CDXS stock opened at $3.07 on Tuesday. The company has a market capitalization of $254.31 million, a price-to-earnings ratio of -3.53 and a beta of 2.12. Codexis, Inc. has a 1-year low of $2.43 and a 1-year high of $6.08. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39. The stock’s fifty day simple moving average is $3.87 and its 200-day simple moving average is $3.95.

Codexis (NASDAQ:CDXS) last released its earnings results on Thursday, February 27th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.09). The business had revenue of $21.46 million for the quarter, compared to analysts’ expectations of $27.41 million. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. On average, sell-side analysts predict that Codexis, Inc. will post -0.77 earnings per share for the current fiscal year.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.